Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Zuberi, Sameer M.
Striano, Pasquale
Rosenow, Felix http://orcid.org/0000-0002-3989-7471
Schubert-Bast, Susanne http://orcid.org/0000-0003-1545-7364
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 22 June 2022
Accepted: 6 February 2023
First Online: 1 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz/GW Pharmaceuticals companies, Marinus Pharma, Precisis, Takeda, UCB, UNEEG medical, and Zogenix. SZ reports research support from Epilepsy Research UK, Scottish Government Digital Health & Care, UCB Pharma, Dravet Syndrome UK, Dravet Syndrome Foundation, Tenovus Foundation and Glasgow Children’s Hospital Charity. He or his institution have received honoraria for consultancy work, educational symposia and advisory boards from GW Pharma, Zogenix, UCB, Encoded Therapeutics, Takeda and Eisai. PS reports personal fees and grants from Angelini Pharma, Eisai, Jazz Pharmaceuticals Biomarin, UCB, Proveca, and Zogenix. FR reports personal fees from Angelini Pharma, Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals companies, and UCB and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the European Union. SSB reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, Ethypharm, UCB, and Zogenix.